{"id":51064,"date":"2022-11-21T11:02:13","date_gmt":"2022-11-21T10:02:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/"},"modified":"2022-11-21T11:02:13","modified_gmt":"2022-11-21T10:02:13","slug":"ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/","title":{"rendered":"Ellipses Pharma to Present Clinical Updates at Leading U.S. Breast and Blood Cancer Conferences"},"content":{"rendered":"
\n

LONDON–(BUSINESS WIRE)–Ellipses Pharma Limited (\u201cEllipses\u201d), a global drug development company focused on accelerating the development of new oncology treatments, is delighted to announce that it will be presenting clinical updates covering two of its assets at the San Antonio Breast Cancer Symposium (SABCS), taking place between 6 \u2013 10 December 2022 in San Antonio, Texas, and at the 64th<\/sup> American Society of Hematology (ASH) Annual Meeting and Exposition, from 10 \u2013 13 December 2022 in New Orleans, Louisiana.\n<\/p>\n

\nAt SABCS, a \u2018Trial in Progress\u2019 poster that details the design of a Phase 1 \/ 2 trial of vosilasarm (EP0062) will be presented. EP0062 is a selective androgen receptor modulator currently under development for the treatment of AR+\/HER-\/ER+ advanced breast cancer.\n<\/p>\n

\nAt ASH, Ellipses\u2019 preliminary results of the dose escalation part of the Phase 1 \/ 2a first-in-human study of EP0042 in patients with acute myeloid leukaemia (AML) will be presented. EP0042 is a dual FLT3 and aurora kinase inhibitor. The trial is investigating the use of EP0042 as both a monotherapy and in combination with existing therapies.\n<\/p>\n

\nDr Rajan Jethwa, CEO of Ellipses Pharma, said:
\n
<\/b>\u201cEllipses is committed to developing novel cancer treatments at pace and getting them to patients. Presenting the design of Ellipses\u2019 first trial of EP0062, and the preliminary findings of the EP0042 trial at two of the world\u2019s leading oncology conferences is a significant step closer to delivering on that goal. We are proud of the work our dedicated team has delivered to make these trials happen and bring such potentially exciting data to light.\u201d\n<\/p>\n

\nProfessor Sir Christopher Evans, Chairman of Ellipses Pharma, said:
\n
<\/b>\u201cThe presentation of these two posters is testament to the potential of the promising assets in Ellipses\u2019 pipeline and demonstrates the progress we have made towards our goal of accelerating the development of much-needed cancer treatments.\u201d\n<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nSABCS: vosilasarm \/ EP0062<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTitle<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nA phase 1\/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+\/HER2-\/ER+ advanced breast cancer\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAuthor(s)<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nElgene Lim, Hendrik-Tobias Arkenau, Sue Brook, Geoff Fisher, Andrew Mazur, Carlo Palmieri\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAbstract number \/ code<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nOT1-02-02\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDate and time<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nTuesday December 6, 2022; 5:00 PM – 6:15 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nSession name \/ category<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nTrial in Progress Session\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLocation<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nHenry B. Gonz\u00e1lez Convention, San Antonio, Texas\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nASH: EP0042<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTitle<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nEP0042, a dual FLT3 and aurora kinase inhibitor: preliminary results of an ongoing phase 1\/2a First in Human (FIH) study in patients with relapsed\/refractory acute myeloid leukaemia (AML)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPresenter<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nDavid Taussig\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAbstract number \/ code<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2768\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDate and time<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nSunday, December 11, 2022; 6:00 PM – 8:00 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nSession name \/ category<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n616. Acute Myeloid Leukaemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLocation<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nErnest N. Morial Convention Center, New Orleans, Louisiana\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nENDS<\/b>\n<\/p>\n

\nAbout Ellipses Pharma Limited
\n
<\/b>Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer medicines and treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimize the time it takes to advance lead products through clinical trials and reach patients.\n<\/p>\n

\nFor more information, please visit ellipses.life<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nEllipses Pharma Ltd
\n
Suzanne Wood
\n
media@ellipses.life<\/a>
www.ellipses.life<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON–(BUSINESS WIRE)–Ellipses Pharma Limited (\u201cEllipses\u201d), a global drug development company focused on accelerating the development of new oncology treatments, is delighted to announce that it will be presenting clinical updates covering two of its assets at the San Antonio Breast Cancer Symposium (SABCS), taking place between 6 \u2013 10 December 2022 in San Antonio, Texas, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51064","6":"format-standard","7":"category-industry"},"yoast_head":"\nEllipses Pharma to Present Clinical Updates at Leading U.S. Breast and Blood Cancer Conferences - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ellipses Pharma to Present Clinical Updates at Leading U.S. Breast and Blood Cancer Conferences - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON–(BUSINESS WIRE)–Ellipses Pharma Limited (\u201cEllipses\u201d), a global drug development company focused on accelerating the development of new oncology treatments, is delighted to announce that it will be presenting clinical updates covering two of its assets at the San Antonio Breast Cancer Symposium (SABCS), taking place between 6 \u2013 10 December 2022 in San Antonio, Texas, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-21T10:02:13+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Ellipses Pharma to Present Clinical Updates at Leading U.S. Breast and Blood Cancer Conferences\",\"datePublished\":\"2022-11-21T10:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\\\/\"},\"wordCount\":539,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\\\/\",\"name\":\"Ellipses Pharma to Present Clinical Updates at Leading U.S. Breast and Blood Cancer Conferences - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-11-21T10:02:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ellipses Pharma to Present Clinical Updates at Leading U.S. Breast and Blood Cancer Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ellipses Pharma to Present Clinical Updates at Leading U.S. Breast and Blood Cancer Conferences - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Ellipses Pharma to Present Clinical Updates at Leading U.S. Breast and Blood Cancer Conferences - Pharma Trend","og_description":"LONDON–(BUSINESS WIRE)–Ellipses Pharma Limited (\u201cEllipses\u201d), a global drug development company focused on accelerating the development of new oncology treatments, is delighted to announce that it will be presenting clinical updates covering two of its assets at the San Antonio Breast Cancer Symposium (SABCS), taking place between 6 \u2013 10 December 2022 in San Antonio, Texas, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-21T10:02:13+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Ellipses Pharma to Present Clinical Updates at Leading U.S. Breast and Blood Cancer Conferences","datePublished":"2022-11-21T10:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/"},"wordCount":539,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/","url":"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/","name":"Ellipses Pharma to Present Clinical Updates at Leading U.S. Breast and Blood Cancer Conferences - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-11-21T10:02:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ellipses-pharma-to-present-clinical-updates-at-leading-u-s-breast-and-blood-cancer-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ellipses Pharma to Present Clinical Updates at Leading U.S. Breast and Blood Cancer Conferences"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51064"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51064\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}